PD180970
PD180970 is a highly potent and ATP-competitive p210Bcr-Abl kinase inhibitor, with an IC50 of 5 nM for inhibiting the autophosphorylation of p210Bcr-Abl. PD180970 also inhibits Src and KIT kinase with IC50s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research[1][2][3].
Product Specifications
CAS Number
287204-45-9
UNSPSC
12352005
Hazard Statement
H301-H413
Target
Apoptosis; Bcr-Abl; c-Kit; Src
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pd180970.html
Purity
99.27
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=C(F)C(C)=C4)N=C3N1C
Molecular Formula
C21H15Cl2FN4O
Molecular Weight
429.27
Precautions
P264-P270-P273-P330-P405-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcr-Abl
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
